Jupiter Neurosciences grants 747,783 options to CEO

Jupiter Neurosciences CEO and Chairman Christer Rosen received a grant of 747,783 stock options for common stock.

Rhea-AI Filing Summary

Jupiter Neurosciences CEO and Chairman Christer Rosen received a grant of 747,783 stock options for common stock. The options have an exercise price of $0.2783 per share and expire on June 2, 2036, giving him the right to buy shares at that price in the future.

According to the disclosure, the options were granted under the company’s 2025 Equity Incentive Plan as a discretionary bonus for services during fiscal 2025. They vest over three years starting on September 2, 2026, in equal quarterly installments, contingent on Rosen’s continued employment.

Insider Trade Summary

Grant/Award: 747,783 shares

Grant/Award 1 txn

Insider ROSEN CHRISTER

Role CEO and Chairman

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	747,783	$0.00	$0.00

Holdings After Transaction: Stock Option — 747,783 contracts (Direct)

Footnotes (1)

1. F1. 747,783 options were granted under the Issuer's 2025 Equity Incentive Plan as a discretionary bonus for services rendered during fiscal 2025. The options vest over three years commencing from September 2, 2026 in equal quarterly installments subject to continued employment through each vesting date.

Key Figures

Option grant size: 747,783 options Exercise price: $0.2783 per share Expiration date: June 2, 2036 +2 more

5 metrics

Option grant size 747,783 options Stock options for common stock granted to CEO and Chairman Christer Rosen

Exercise price $0.2783 per share Exercise price of granted stock options

Expiration date June 2, 2036 Option expiration for CEO grant

Vesting start September 2, 2026 Vesting begins; options vest quarterly over three years

Shares underlying options 747,783 shares Underlying common stock linked to the option grant

Key Terms

Stock Option, 2025 Equity Incentive Plan, discretionary bonus, vest, +1 more

5 terms

Stock Option financial

"Stock Option"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

2025 Equity Incentive Plan financial

"granted under the Issuer's 2025 Equity Incentive Plan as a discretionary bonus"

discretionary bonus financial

"as a discretionary bonus for services rendered during fiscal 2025"

vest financial

"The options vest over three years commencing from September 2, 2026 in equal quarterly installments"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

exercise price financial

"conversion_or_exercise_price": "0.2783""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did JUNS CEO Christer Rosen report on this Form 4?

Christer Rosen reported receiving a grant of 747,783 stock options. These options give him the future right to purchase Jupiter Neurosciences common stock, reflecting compensation for services during fiscal 2025 under the company’s 2025 Equity Incentive Plan.

How many Jupiter Neurosciences (JUNS) options were granted to the CEO?

The CEO received 747,783 stock options linked to Jupiter Neurosciences common stock. Each option represents the right to buy one share at a fixed exercise price, forming part of a discretionary bonus for services rendered in fiscal 2025.

What is the exercise price and expiration date of the JUNS CEO option grant?

The granted options have an exercise price of $0.2783 per share and expire on June 2, 2036. This means the CEO can buy shares at $0.2783 any time before that expiration, once the options have vested.

How do the 747,783 Jupiter Neurosciences options granted to the CEO vest?

These options vest over three years starting September 2, 2026, in equal quarterly installments. Vesting is subject to Christer Rosen’s continued employment through each vesting date, so the full award becomes exercisable gradually over that three-year period.

Under which plan were the new JUNS CEO stock options granted?

The 747,783 options were granted under Jupiter Neurosciences’ 2025 Equity Incentive Plan. The filing describes them as a discretionary bonus for services rendered during fiscal 2025, aligning executive compensation with the company’s equity-based incentive framework.

Is the JUNS CEO option grant an open-market purchase of stock?

No, this transaction is a grant of stock options, not an open-market share purchase. The CEO receives options at no cash cost now, with the right to buy shares later at $0.2783 per share once vesting conditions are met.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/04/2026 - 09:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ROSEN CHRISTER

(Last) (First) (Middle)

C/O JUPITER NEUROSCIENCES, INC.

1001 NORTH US HYWAY 1, SUITE 504

(Street)

JUPITER FLORIDA 33477

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
JUPITER NEUROSCIENCES, INC. [ JUNS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and Chairman

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$0.2783	06/02/2026		A		747,783		(1)	06/02/2036	Common Stock	747,783	$0	747,783	D

Explanation of Responses:

1. 747,783 options were granted under the Issuer's 2025 Equity Incentive Plan as a discretionary bonus for services rendered during fiscal 2025. The options vest over three years commencing from September 2, 2026 in equal quarterly installments subject to continued employment through each vesting date.

	/s/ Christer Rosen	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)